Table 4.
Gemcitabine Combinations.
| Study | Treatment | N | Response Rate (%) | Median Time to Progression | Median Overall Survival |
|---|---|---|---|---|---|
| Doval et al 59 | Gemcitabine + cisplatin | 39 | 37% | 4.5 months | 5 months |
| Park et al.58 | Gemcitabine + cisplatin | 35 | 17% | 3.5 months | 8.3 months |
| Malik et al.60 | Gemcitabine + cisplatin | 11 | 64% | 6.5 months | 10 months |
| Reyes-Vidal et al 61 | Gemcitabine + cisplatin | 44 | 48% | 7 months | |
| Tan et al.22 | Gemcitabine + carboplatin | 13 | 31% | ||
| Knox et al.3 | Gemcitabine + Capecitabine | 45 | 31% | 7 months | 14 months |
| Chang et al 23 | Gemcitabine + Capecitabine | 34 | 12% | 2.6 months | 7.8 months |
| Verderame et al 24 | Gemcitabine + Oxaliplatin | 24 | 50% | 12 months | |
| Wagner et al 25 | Gemcitabine + Oxaliplatin + CI 5-FU | 35 | 9.9 months | ||
| NCCTG 26 | Gemcitabine + CI 5-FU/LV | 42 | 9.5% | 4.6 months | 9.7 months |
| Knox 27 | Gemcitabine + CI 5-FU/LV | 27 | 33% | 3.7 months | 5.3 months |
| Knox et al.3 | Gemcitabine + Capecitabine | 45 | 31% | 7 months | 14 months |